MT-1

MT-1 (Afamelanotide) Nasal Spray is supplied by Crystal Peptides as a catalogued research material in this format and strength: nasal spray, 10mg/10ml. This presentation is listed for laboratory research, not as a medicinal product.

MT-1 is a market name associated with afamelanotide, also known as NDP-alpha-MSH, a linear analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Assignment of this identity requires supplier specifications and a batch-specific certificate of analysis (CoA) confirming the full sequence, stereochemistry, terminal modifications and salt or counter-ion. The catalogue name alone does not establish equivalence to a characterized afamelanotide reference material or authorized active substance.

Chemical properties and registry information

The sequence and registry values describe the specified peptide entity, not the complete spray formulation. Their applicability depends on confirmation of the batch identity and material form; molecular mass does not describe excipients or counter-ion contributions.

Research background and published evidence

Published research

NDP-alpha-MSH/afamelanotide has been investigated in melanocortin receptor and biochemical research, including studies concerned with melanocortin 1 receptor (MC1R) signalling and pigmentation biology. Published work addresses the relationship between peptide structure, receptor interactions and melanogenesis. Interpretation requires attention to the characterized material, experimental model and formulation rather than reliance on a shared compound name.

Current scientific understanding

Afamelanotide is a linear alpha-MSH analogue and is structurally distinct from cyclic Melanotan II. Evidence concerning the latter cannot establish the properties of MT-1. Likewise, literature and regulatory information for characterized afamelanotide products do not authenticate this catalogue spray or establish its composition, stability or experimental comparability. Afamelanotide is an active substance in an authorized prescription medicinal product; this research presentation is not that product.

Formulation note

Published research has mostly used other materials, formulations or routes rather than this catalogue nasal spray. Findings from injected or differently formulated material cannot be transferred to this nasal spray formulation. The formulation matrix, excipient composition and peptide integrity require presentation-specific assessment. The stated format and strength do not establish equivalence to materials described in published studies, and no formulation-specific performance is implied.

Quality and testing

Quality documentation must be linked to the exact nasal spray presentation and batch. Consult the matching CoA for reported identity, analytical methods, acceptance criteria and results, with the SDS providing complementary composition and hazard information. A report for a powder, another strength or another lot is not evidence for this product.

Chromatographic area purity, peptide identity, analyte content, degradation products, microbiological quality and elemental impurities are separate analytical questions. One measurement does not establish the others. Only tests documented in an available, matching batch report should be treated as verified; the catalogue strength is not a substitute for batch-specific analytical evidence.

For research use only by qualified professionals. Not for human or veterinary use. No dosing directions are provided.